5 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 12 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Recruiting 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Suspended 1 |
Follow Testosterone Propionate: new trials by email Literature Review of Testosterone Propionate trials Research Report on Testosterone Propionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Recruiting | University of Washington | 69 | 2024-05-21 | 2026-07-21 |
| Testosterone Treatment in Men With Chronic Kidney Disease Jatenzo Pill - Hypogonadism, Male, Kidney Disease, Chronic | Phase 2 | Recruiting | St. Louis University | 20 | 2022-03-15 | 2026-04-30 |
| Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer Testosterone Undecanoate, Enzalutamide - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 15 | 2022-03-07 | 2026-09-29 |
| Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study Aveed 750 MG in 3 ML IM Injection, Normal Saline 3 ML IM Injection - Muscle Atrophy, Surgery | Phase 2 / Phase 3 | Unknown | The Stone Research Foundation for Sports Medicine and Arthritis | 15 | 2020-05-08 | 2021-08-31 |
| COMbination of Bipolar Androgen Therapy and Nivolumab Testosterone cypionate, Nivolumab - Castration-resistant Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 45 | 2018-09-05 | 2024-02-20 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
| A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels Testosterone Solution 2%, Placebo Solution - Ejaculatory Dysfunction, Hypogonadism | Phase 2 | Completed | Eli Lilly and Company | 76 | 2011-08-01 | 2014-12-19 |
| A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations Testosterone MD-Lotion - Hypogonadism | Phase 2 | Completed | Eli Lilly and Company | 21 | 2007-10-01 | 2011-01-07 |
| Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. Testosterone propionate - Vaginitis, Dyspareunia | Phase 1 / Phase 2 | Suspended | University of Vermont | 30 | 2006-12-01 | 2010-05-13 |
| Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease therapeutic estradiol, deslorelin, therapeutic testosterone - brca1 Mutation Carrier, brca2 Mutation Carrier | Phase 2 | Unknown | City of Hope Medical Center | 11 | 2004-03-11 | 2024-08-28 |
| Testosterone Replacement Therapy in Chronic Spinal Cord Injury Testosterone Transdermal System (Androderm 5 mg patch) - Spinal Cord Injury, Hypogonadism | Phase 2 / Phase 3 | Completed | VA Office of Research and Development | 31 | 2003-08-01 | 2017-11-01 |
Prostatic Neoplasms (4) · Hypogonadism (3) · Breast Neoplasms (2) · Disease (1) · Dyspareunia (1) · Ejaculatory Dysfunction (1) · Erectile Dysfunction (1) · Eunuchism (1) · Knee Injuries (1) · Muscular Atrophy (1) · Renal Insufficiency, Chronic (1) · Sexual Dysfunction, Physiological (1) · Sexual Dysfunctions, Psychological (1) · Spinal Cord Injuries (1) · Vaginitis (1)
Eli Lilly and Company (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Washington (2) · City of Hope Medical Center (1) · ECOG-ACRIN Cancer Research Group (1) · St. Louis University (1) · The Stone Research Foundation for Sports Medicine and Arthritis (1) · University of Vermont (1) · VA Office of Research and Development (1)
United States (11) · Canada (1)
Michael Schweizer (2) · Hyman Muss, MD (1) · Jeffrey Weitzel, MD (1) · Mani Vessal, Ph.D. (1) · Marie Wood, MD (1) · Mark Markowski, MD, Ph.D (1) · Michael T. Schweizer (1) · Sabrina M Witherby, MD (1) · Samuel Denmeade, MD (1) · Sandeep Dhindsa, MD (1) · William Bauman, MD (1)
PMID 21252493, PMID 21717386, PMID 23343764, PMID 24968251, PMID 26158605, PMID 38167882, PMID 38224135
P30CA015704 (1), P30CA033572 (1), P50CA097186 (1), U10CA180820 (1)